Skandinaviska Enskilda Banken (SEB)
XLRN

Skandinaviska Enskilda Banken (SEB)’s Acceleron Pharma XLRN Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-65,516
Closed -$11.3M – 1097
2021
Q3 		$11.3M Sell
65,516
-26,971
-29% -$3.53M 0.06% 263
2021
Q2 		$11.6M Buy
92,487
+78,180
+546% +$9.86M 0.07% 260
2021
Q1 		$1.94M Buy
14,307
+4,207
+42% +$543K 0.01% 666
2020
Q4 		$1.29M Buy
10,100
+4,700
+87% +$551K 0.01% 764
2020
Q3 		$608K Sell
5,400
-5,700
-51% -$567K ﹤0.01% 807
2020
Q2 		$1.06M Buy
+11,100
New +$1.07M 0.01% 717

Skandinaviska Enskilda Banken (SEB)'s XLRN Position: Q4 2021 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 65,516 shares — an estimated $11.3M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in XLRN in Q2 2020 and held it in 6 quarters. The position peaked at $11.6M in Q2 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 65,516 Acceleron Pharma shares in Q4 2021, an estimated $11.3M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Acceleron Pharma in Q2 2020 and held it in 6 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Acceleron Pharma position peaked at $11.6M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2021, filed 10 Feb 2022.